FASN and colorectal cancer: FASN over-expression in PDX model and SW480 colon cancer cells led to an upsurge in the expression of SphK2 but also of SphK1 by activating ERK1/2, while pharmacological inhibition of FASN specifically suppressed the expression of SphK2 in primary colorectal cancer cells and PDX model of metastatic colorectal cancer.